News >

VCD Induction Induces High Response Rates in Myeloma

Jason Harris
Published: Thursday, Oct 12, 2017

Hermann Einsele, MD
Hermann Einsele, MD
Induction therapy with bortezomib (Velcade), cyclophosphamide, and dexamethasone (VCD) induced strong response rates in treatment-naïve patients with multiple myeloma, according to phase II results from the DSMM XI trial published in the British Journal of Haematology.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication